行情

OTIC

OTIC

Otonomy
NASDAQ

实时行情|Nasdaq Last Sale

3.370
-0.180
-5.07%
休市 16:00 01/24 EST
开盘
3.580
昨收
3.550
最高
3.600
最低
3.150
成交量
24.76万
成交额
--
52周最高
4.180
52周最低
1.960
市值
1.04亿
市盈率(TTM)
-2.2194
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

OTIC 新闻

  • 沙特预计新型冠状病毒对石油需求的影响“非常有限”
  • 新浪财经.43分钟前
  • 盖茨基金会捐款500万美元 支持中国抗击武汉肺炎疫情
  • 新浪科技.58分钟前
  • 日经225指数开盘下跌1.7%,报23,427.90。
  • 新浪财经.1小时前
  • 达美航空因驱赶穆斯林乘客下机被罚款5万美元
  • 新浪财经综合.1小时前

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

OTIC 简况

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.
展开

Webull提供Otonomy Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。